Adjuvant Thalidomide and Metronomic Chemotherapy for the Treatment of Canine Malignant Mammary Gland Neoplasms

Autor(es)

De Campos, Cecilia Bonolo ^{[1, 2]} ; Lavalle, Gleidice Eunice ^[3] ; Monteiro, Lidianne Narducci ^[4] ; Arantes Pegas, Gabriela Rafaela ^[1] ; Fialho, Silvia Ligorio ^[5] ; Balabram, Debora ^[6] ; Cassali, Geovanni Dantas ^[1]

Afiliação do(s) autor(es)

^[1] Fed Univ Minas Gerais UFMG, Dept Gen Pathol, Lab Comparat Pathol, Belo Horizonte, MG - Brazil

^[2] Sao Paulo State Univ FCAV UNESP, Dept Vet Clin & Surg, Sch Agr & Vet Sci, Jaboticabal - Brazil

^[3] Fed Univ Minas Gerais UFMG, Vet Sch, Dept Vet Clin & Surg, Belo Horizonte, MG - Brazil

^[4] Vet Pathol Diagnost Consultancy Codivet, Vitoria - Brazil

^[5] Fundacao Ezequiel Dias, Dept Pharmaceut & Biotechnol Dev, Belo Horizonte, MG - Brazil

^[6] Educ & Res Inst Santa Casa BH, Belo Horizonte, MG - Brazil

• Tipo de documento: Artigo Científico
• Fonte: IN VIVO; v. 32, n. 6, p. 1659-1666, NOV-DEC 2018.
• Citações Web of Science: 2

Resumo

Background/Aim: The aim of the present study was to evaluate a multimodal approach for the treatment of canine malignant mammary gland neoplasms, including surgery, chemotherapy, thalidomide, and metronomic chemotherapy (MC). Materials and Methods: Fifty-eight female dogs were submitted to four different treatments: surgery; surgery with chemotherapy; surgery with chemotherapy and thalidomide; and surgery with chemotherapy and metronomic chemotherapy and overall survival was evaluated. Results: No statistical difference was found in the proliferative index and microvessel density of primary neoplasms and distant metastases following thalidomide treatment. Diffuse intense inflammatory infiltrate was predominant in primary tumors and diffuse moderate inflammatory infiltrate in metastatic lesions. No statistically significant difference was observed in median survival time (MST) between treatment groups when including all clinical stages (p=0.3177). However, animals diagnosed with distant metastasis treated with surgery and chemotherapy associated with thalidomide or MC presented longer MST when compared to animals treated only with surgery or surgery and chemotherapy (p<0.0001). Conclusion: The proposed multimodal therapy protocols including antiangiogenic and immunomodulatory therapies demonstrated a clinical benefit for patients in advanced clinical stages. (AU)

• Processo FAPESP: 14/01329-9 - Avaliação da terapia com talidomida em neoplasias malignas da glândula mamária canina
• Beneficiário: Cecília Bonolo de Campos
• Modalidade de apoio: Bolsas no Brasil - Doutorado